Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated ...
Hosted on MSN1mon
Gyre Therapeutics president Ma Songjiang sells $42,760 in stockSAN DIEGO—Ma Songjiang, President of Gyre Therapeutics, Inc. (NASDAQ:GYRE), a biotechnology company currently valued at $968 million, recently sold a total of 4,000 shares of the company's ...
Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $10.70, but opened at $12.43. Gyre Therapeutics shares ...
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback